4.5 Article

Clinical features of childhood-onset paroxysmal kinesigenic dyskinesia with PRRT2 gene mutations

Journal

DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
Volume 55, Issue 4, Pages 327-334

Publisher

WILEY
DOI: 10.1111/dmcn.12056

Keywords

-

Funding

  1. Reta Lila Weston Trust
  2. Muscular Dystrophy Campaign
  3. The Medical Research Council
  4. Wellcome Trust
  5. Parkinson's UK
  6. Parkinson's Foundation
  7. NIHR UCLH/UCL Biomedical Research Centre (CBRC)
  8. Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
  9. Dystonia Medical Research Foundation
  10. Reta Lila Weston Fellowship
  11. Action Medical Research
  12. Action Medical Research [1722] Funding Source: researchfish
  13. Medical Research Council [G1001253, G108/638, MR/J004758/1, G0802760] Funding Source: researchfish
  14. MRC [MR/J004758/1, G0802760, G108/638, G1001253] Funding Source: UKRI

Ask authors/readers for more resources

Aim To define better the phenotype and genotype of familial and sporadic cases of paroxysmal kinesigenic dyskinesia (PKD) caused by mutations in the PRRT2 gene presenting in the paediatric age group. Method We report the detailed clinical and molecular genetic features of 11 patients (six females, five males) with childhood-onset PRRT2-mutation-positive PKD. Results Mean age at disease onset was 8years 7.5months (range 511y), and clinical presentation was characterized by daily short paroxysmal episodes of dystonia/dyskinesia. Most patients also had non-kinesigenic attacks in addition to the classical movement-induced paroxysmal episodes. One family demonstrated great phenotypic variability with PKD, infantile convulsions, and/or hemiplegic migraine affecting different family members with the same mutation. All patients in whom antiepileptics (carbamazepine/phenytoin) were tried showed a dramatic improvement with complete abolition of dyskinetic episodes. Interpretation Our case series provides a detailed clinical description of patients with PRRT2-PKD, and reports a spectrum of disease-causing mutations, thereby expanding both the clinical phenotype and mutation spectrum of disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available